4th Dec 2006 14:35
GlaxoSmithKline PLC04 December 2006 Issued - Monday 4 December 2006 LANDMARK STUDY SHOWS AVANDIA(R) IS MORE EFFECTIVE THAN METFORMIN OR A SULPHONYLUREA IN LONG-TERM BLOOD SUGAR CONTROL IN TYPE 2 DIABETES Avandia Reduces Risk of Monotherapy Failure at Five Years Results from ADOPT (A Diabetes Outcome Progression Trial) demonstrated thatinitial treatment with Avandia(R) (rosiglitazone maleate) reduced the risk ofmonotherapy failure in people with type 2 diabetes by 32 percent compared tometformin (p180 mg/dl (10 mmol/l) to a lower blood sugar level moreconsistent with current therapeutic approaches, FPG 140 mg/dl (7.8 mmol/l).1,6,7 Long-term blood glucose control as measured by a mean HbA1cRelated Shares:
Glaxosmithkline